First-Line Treatment Using Combination Therapy in Advanced RCC

TKI and PD-L1 Therapy Combinations Show Long-Term Durability in Advanced RCC

In this Q&A discussion, Hans Hammers, MD, PhD, explains the rationale for continued use of tyrosine kinase inhibitor and PD-L1 therapy combinations, like lenvatinib and pembrolizumab, for patients with advanced renal cell carcinoma.

Oncology Nurses Discuss Adverse Event Management in mRCC Treatment

During a live virtual event, Sarah Yenser Wood, RN, MSN, ANP, AOCNP, and a panel of oncology nurses discussed their approaches to management of patients receiving first-line regimens for advanced or metastatic renal cell carcinoma.

Favorable Efficacy and Tolerability for Lenvatinib/Pembrolizumab in RCC

Pedro C. Barata, MD, MSc, explains how the favorable efficacy and tolerability of lenvatinib and pembrolizumab observed in the CLEAR trial helps provide a standard of care in this patient population.

Managing Frontline Toxicities in Patients With RCC

During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed with participants their experiences managing toxicities of frontline combination therapy for renal cell carcinoma. This is the second of 2 articles based on this event.

IO/IO Versus IO/TKI Frontline Therapy for Intermediate-Risk RCC

During a Targeted Oncology case-based roundtable event, Moshe Ornstein, MD, MA, discussed the factors influencing the choice of frontline therapy for a patient with stage IV clear cell renal cell carcinoma whose risk status was intermediate.

Discussing Real-World Experience Using Lenvatinib in Advanced RCC

During a Targeted Oncology case-based roundtable event, Robert J. Motzer, MD, discussed with participants their experiences using lenvatinib in treatment of advanced renal cell carcinoma. This is the second of 2 articles based on this event.

Using Risk Stratification to Determine Frontline Treatment for ccRCC

During a live virtual event, Robert J. Motzer, MD, discussed the role of risk assessment in treating a patient with clear cell renal cell carcinoma. This is the first of 2 articles based on this event.

Lenvatinib/Pembrolizumab for mRCC Shows Efficacy and Limited Treatment Discontinuation

During a live virtual event, Thomas Hutson, DO, PharmD, discussed the outcomes of the CLEAR trial of lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma.

Comparing IO/IO and IO/TKI Frontline Regimens in Clear Cell RCC

During a live virtual event, Thomas Hutson, MD, PharmD, discussed the 4 frontline combination regimens including immunotherapies and tyrosine kinase inhibitors. This is the first of 2 articles based on this live event.

Part 2: Managing Cabozantinib/Nivolumab and other First-Line RCC Regimens

During a live virtual event, Brian Rini, MD, discussed how the combination of cabozantinib plus nivolumab compares with lenvatinib plus pembrolizumab in terms of tolerability and management in patients with advanced renal cell carcinoma.

Part 1: Selecting Systemic IO and TKI Options for Clear Cell RCC

During a live virtual event, Brian Rini, MD, discussed the efficacy and tolerability of approved first-line tyrosine kinase inhibitor and immunotherapy combinations for patients with advanced renal cell carcinoma.

Managing Adverse Events with Superior Combination Therapies in RCC

Thomas Hutson, MD, PharmD, discusses management strategies when confronting adverse events using combination therapies in treating patients with renal cell carcinoma.

Vogelzang Discusses Significant PFS Benefit of Lenvatinib/Pembrolizumab in RCC

During a live virtual event, Nicholas J. Vogelzang, MD, discussed the results of the CLEAR trial of lenvatinib for patients with advanced renal cell carcinoma.

Weighing High Response Rates Versus Tolerability in Frontline RCC

During a live virtual event, Moshe Ornstein, MD, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and participants' experiences with these agents.

Vaishampayan Discusses PFS Benefit With Lenvatinib/Pembrolizumab in RCC

During a live virtual event, Ulka Vaishampayan, MBBS, discussed the results of the CLEAR trial of lenvatinib and pembrolizumab compared with sunitinib in first-line treatment of advanced RCC.

Part 2: Tolerability of Immunotherapy plus TKI Inhibitors in RCC

During a live virtual event, Sandy Srinivas, MD, discussed the tolerability of the tyrosine kinase inhibitor/immunotherapy combinations cabozantinib plus nivolumab and lenvatinib plus pembrolizumab, compared with the dual immunotherapy ipilimumab plus nivolumab.

Part 1: Real-World Experience With Dosing Lenvatinib/Pembrolizumab in RCC

During a live virtual event, Sandy Srinivas, MD, discussed results from the CLEAR trial of lenvatinib and pembrolizumab in renal cell carcinoma and the participants' experiences with the regimen including dose reductions needed by their patients across multiple cancer types.